By Digifin Pty Ltd · About this coverage
Key Points
- First patient-specific ROXUS prescriptions fulfilled in the US via Mavrox and Strive
- Marks start of prescription activity under Shed telehealth and Strive Pharmacy deals
- ROXUS compounded under Section 503A; not FDA-reviewed or approved for safety or efficacy
- No prescription volumes, revenue or pricing disclosed in the release
About LTR Pharma (ASX:LTP)
LTR Pharma Limited is an ASX-listed pharmaceutical company developing and commercialising intranasal therapies. Its products include fast-acting sprays for erectile dysfunction and a pipeline candidate for oesophageal motility disorders, with commercial activity in Australia and partner channels in other markets.
LTR Pharma (ASX:LTP) said the first patient-specific ROXUS prescriptions received through Mavrox, Shed's men's health telehealth platform, have been fulfilled in the United States, marking the start of ROXUS prescription activity under its Shed and Strive Pharmacy arrangements.
ROXUS is LTR Pharma's intranasal medication for erectile dysfunction support, compounded and dispensed in the United States by a licensed pharmacy under the patient-specific compounding provisions of Section 503A of the US Federal Food, Drug, and Cosmetic Act. Strive Pharmacy has established systems to receive, compound and fulfil valid patient-specific prescriptions. LTR Pharma will focus on supporting US partners as prescribing builds and will update when meaningful prescription activity information is available. The release states ROXUS is not reviewed or approved by the FDA for safety or efficacy, and compounded drugs are intended for patients whose prescriber determines needs are not met by an available FDA-approved drug. The announcement does not disclose prescription volumes, revenue or pricing.
Source: LTR Pharma Limited (ASX:LTP), 6 October 2026. Summary content supplied by Digifin Pty Ltd.
News summary only, not financial advice. It does not consider your objectives, financial situation or needs.